Baxter International Inc. plans to invest as much as $200 million in equity in companies with promising early-stage therapies through its new Baxter Ventures fund. “Baxter’s mission is to apply innovative science to develop therapies and medical technologies that save and sustain patients’ lives,” said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. “As the company’s internal capabilities have advanced our late-stage pipeline, we have the capacity to further accelerate ...